CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Inclusion Criteria:

• Males or females ≥ 50 and ≤ 80 years at the time of signing the ICF

• Diagnosed of choroidal neovascularization (CNV) secondary to AMD in the study eye;

• Best-corrected visual acuity (BCVA) ranged from 73 to 23 early treatment diabeticretinopathy study (ETDRS)letter score (corresponding to 20/32 to 20/320 of Snellenvisual acuity) in the study eye;

• BCVA in the non-study eye had an ETDRS letter score of 19(equivalent to Snellenvisual acuity20/400) and above;

• Able to perform visual acuity and retinal function tests and able and willing tocomply with study procedures for this clinical trial;

RESPONSIVE SUBJECTS:

• History of need for and responsive to anti-VEGF therapy in the study eye

NON-RESPONSIVE SUBJECTS:

• History of receiving anti-VEGF therapy but is resistant to treatment, which isdefined as: a. complete or near-complete remission of subretinal fluid after theinitial 3 doses of anti-VEGF agents and thenno improvement (less than 50umreduction) or deterioration of CRT by OCT

Exclusion Criteria:

• Subretinal hemorrhage, scarring, or fibrosis of greater than 50% of the total lesionin the study eye;

• Any condition in the Investigator's opinion that could limit visual improvement inthe study eye;

• Other ocular diseases that may affect central vision in the study eye (e.g., retinalvein occlusion, retinal detachment, macular hole, optic nerve disease, etc.);

• Presence of CNV not due to nAMD in the study eye,

• Uncontrolled glaucoma in the study eye;

• Active intraocular inflammation or a history of uveitis in either eye;

• History or presence of corneal dystrophy in the study eye;

• Subjects with immunodeficiency diseases prone to opportunistic infections;

• History of other intraocular surgery in the study eye within 3 months prior tobaseline that in the Investigator's opinion could impact healing or study outcomeinterpretation;

• Prior gene therapy or oligonucleotide therapy;

• History of acute coronary syndrome, myocardial infarction, coronaryrevascularization, cerebrovascular accident, or transient ischemic attack within 6months prior to the Screening Visit;

• Other conditions judged by the investigator as inappropriate for the study.